Progression in smoldering Waldenström macroglobulinemia: long-term results
Open Access
- 10 May 2012
- journal article
- Published by American Society of Hematology in Blood
- Vol. 119 (19), 4462-4466
- https://doi.org/10.1182/blood-2011-10-384768
Abstract
The purpose of this study was to define the risk of progression and survival of patients with smoldering Waldenström macroglobulinemia (SWM). SWM isThis publication has 21 references indexed in Scilit:
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myelomaLeukemia, 2008
- Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myelomaBlood, 2008
- Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple MyelomaThe New England Journal of Medicine, 2007
- Immunoglobulin free light chains and solitary plasmacytoma of boneBlood, 2006
- Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significanceBlood, 2005
- Asymptomatic Waldenstrom's macroglobulinemiaSeminars in Oncology, 2003
- Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- Incipient myelomatosis or «essential« hyperglobulinemia with fibrinogenopenia — a new syndrome?Acta Medica Scandinavica, 1944